Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorBaptist Health South Florida
About this trial
The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In addition, this study will look at the changes of the treated brain metastases using this imaging agent over time.
Eligibility criteria
Qualifiers
Male or female, age ≥18 years
Performance status, Eastern Cooperative Oncology Group 0-2
Confirmed diagnosis of brain metastases with at least one untreated lesion >2 cm in maximum diameter
Plan for SSRS per the treating team
Disqualifiers
Prior anaphylactic reaction to 18F-fluciclovine
Evidence of leptomeningeal disease
Prior whole-brain radiation therapy
Contraindication to MRI (e.g., due to safety reasons, such as presence of a pacemaker)
Trial design
Treatments tested in this trial
- 18F fluciclovine
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Baptist Health South Florida
Lead sponsor
Blue Earth Diagnostics
Collaborator
Source ClinicalTrials.gov